Paul Wright Email & Phone Number

San Diego, CA, US

Sydney, New South Wales, AU

• Directed CMC activities for Imugene’s CF33 oncolytic virus and B-cell vaccine programs in a fully remote role.
• Oversaw process, analytical and formulation development, along with external manufacturing of clinical trial materials at CDMOs.

• Provided consulting regarding CMC development for viral therapeutics, resulting in full-time senior level role with client.

New York, New York, US

• Led a high-performing team of 14 scientists, advancing virus and protein-based projects from discovery to First-in-Human (FIH) trials.
• Oversaw development and manufacturing processes for cutting-edge vaccine candidates, including mRNA, oncolytic viruses, and viral vectors.
• Contributed to strategic leadership as a member of the Cancer Vaccines and Immunotherapeutics Executive Leadership Team.
• Pioneered mRNA production and LNP formulation capabilities, enhancing the group's expertise in novel vaccine technologies.
• Directed CMC efforts for an innovative adenovirus/mRNA-based cancer vaccine program, managing all development and manufacturing aspects.
• Established bispecific antibody production capabilities, expanding the team's technical repertoire.

New York, New York, US

• Managed a team of up to 14 scientists, driving virus and protein-based projects from discovery through FIH stages.
• Led process development for oncolytic virus projects, including a tripartite collaboration with a key collaborator and international CDMO.
• Invented a novel production/purification process for oncolytic vaccinia virus, achieving over 50-fold increase in virus production and 200-fold improvement in purity (see patents).
• Executed successful tech transfer and scale-up to a 500 m² bioreactor process, overseeing Phase 1 clinical trial manufacturing at a CDMO.
• Authored CMC sections for IND filings, receiving no regulatory queries, demonstrating excellence in regulatory compliance.
• Evaluated and selected CDMOs, representing the department during RFP processes to ensure optimal partnerships.

New York, New York, US

• Directed a team of 11 scientists in developing production processes for diverse vaccine candidates, including proteins, conjugates, viral vectors, and viruses.
• Managed tech transfers of developed processes to internal sites or CDMOs for clinical trial production, ensuring seamless transitions.
• Led cross-functional teams for anti-PCSK9 and anti-IgE peptide-CRM197 vaccine programs, overseeing process, analytical, and formulation development.
• Advanced influenza vaccine development by leading upstream and downstream processes for whole inactivated virus vaccines across multiple strains.
• Streamlined adenovirus production, successfully transferring processes from a CDMO and overseeing internal production for regulatory toxicology studies.

New York, New York, US

• Managed and mentored staff, including direct supervision of two scientists and matrix leadership of junior team members.
• Core team member for multiple viral and therapeutic vaccine programs, contributing to strategic project development.
• Ensured project continuity by overseeing equipment and team relocation from the UK to the USA.
• Directed protein expression and cell culture operations, enhancing the team's capabilities in mammalian systems.
• Led early-stage process development for a clinical small molecule-conjugated vaccine targeting nicotine addiction.
• Developed methods for virus-like particles (VLPs), and viral glycoproteins production for pre-clinical studies and transferred methods to partner lines.

New York, New York, US

• Spearheaded cell culture and fermentation projects, designing and executing upstream process characterization and second-generation production processes.
• Collaborated across disciplines and sites, contributing to process validation and co-development for multiple monoclonal antibody (mAb) projects.
• Led upstream process characterization for a lead mAb project, overseeing scale-up and PPQ batches at a CDMO.
• Developed a scale-down model replicating 12,000 L production performance at a 1.8 L laboratory scale.
• Establised a perfusion-based mAb production system, achieving a 10-fold increase in volumetric antibody output over the fed-batch platform process.
• Created proprietary serum-free media and feeds, matching production levels of commercial formulations through systematic DOE approaches.